Roivant Sciences (ROIV) EBITDA (2020 - 2025)

Roivant Sciences has reported EBITDA for 6 years, with the latest figure at -$339.2 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA fell 23.61% year-over-year to -$339.2 million; the trailing twelve-month figure through Dec 2025 stood at -$1.2 billion (down 127.32% YoY), and the FY2026 full-year result was -$515.1 million, up 48.66% from the prior year.
• EBITDA for Q4 2025 stood at -$339.2 million, down from -$306.2 million in the prior quarter.
• The five-year high for EBITDA was $5.1 billion in Q4 2023, with the low at -$684.4 million in Q3 2021.
• Historically, EBITDA has averaged $64.2 million across 5 years, with a median of -$280.8 million in 2022.
• Annual changes were most pronounced in 2021 — EBITDA plunged 337.22% — and 2023, when it soared 1456.19%.
• Roivant Sciences' EBITDA stood at -$246.0 million in 2021, then tumbled by 53.68% to -$378.1 million in 2022, then soared by 1456.19% to $5.1 billion in 2023, then tumbled by 105.35% to -$274.4 million in 2024, then declined by 23.61% to -$339.2 million in 2025.
• The last three EBITDA figures came in at -$339.2 million (Q4 2025), -$306.2 million (Q3 2025), and -$284.9 million (Q2 2025), per Business Quant data.